Tag: Hep C treatment

Does price dictate HCV drug policy?

By Amanda Fletcher

Early this year, British Columbia, Alberta, Saskatchewan, Quebec and Ontario announced the lowering of eligibility requirements for access to public coverage for life-changing hepatitis C drugs, including EPCLUSA™ (sofosbuvir/velpatasvir) – the first once-daily, pan-genotypic single tablet regimen for the treatment of chronic HCV infection. These drugs will be available to those with lower fibrosis scores for the first time (the greater the fibrosis score, the more severe the liver scarring, or cirrhosis, caused by disease.)[i]